Rerouting the GPS Directing Immunotherapy in Endometrial Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37698948.
- Also identified by DOI 10.1158/1078-0432.CCR-23-1953.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mismatch repair (MMR) status alone is insufficient to guide the use of PD-(L)1 monotherapy in patients with endometrial cancer. Additional biomarkers, including tumor mutational burden and combined positive score, may help to identify patients with MMR-proficient tumors with a high probability of benefit from PD-(L)1 monotherapy, and those with MMR-deficient tumors who might require combination strategies. See related article by Oaknin et al., p. 4564.
Medical subject headings
- Endometrial Neoplasms
- Colorectal Neoplasms
- Neoplastic Syndromes, Hereditary